The work was designed as a pathway-efficiency study rather than as a validation of an independent diagnostic instrument. That distinction is essential because the two first-stage measures are themselves components of the liver frailty index, or LFI, which served as the reference standard for defining frailty. This shared structure creates incorporation bias, meaning the first-stage tests and the reference standard are not fully independent. The investigators therefore framed the results as triage performance within the cohort, not as evidence that the rapid screen is a stand-alone diagnostic test, is clinically safe, or should immediately replace routine assessment. The study was conducted at a tertiary hospital in southern China from August 2021 through August 2025. All 606 enrolled participants were inpatients, and the analysis did not include outpatients.

Among all 606 patients, the LFI classified 100, or 16.5%, as robust, 393, or 64.9%, as pre-frail, and 113, or 18.6%, as frail. Frailty was defined as an LFI score of 4.5 or higher, pre-frailty as 3.2 to less than 4.5, and robustness as a score below 3.2. The main pathway analysis included 604 patients, comprising 112 frail and 492 non-frail patients, after two patients with missing grip-strength data were excluded. A separate complete-component analysis included 600 patients. The first-stage thresholds were selected from the full analytic sample by maximizing the Youden index against the frailty threshold. A patient screened positive if five chair stands took at least 16.55 seconds or grip strength was 23.42 kilograms or less. Under a prespecified safety rule, bedridden patients who could not attempt the chair-stand test were automatically classified as screen-positive so that inability to perform the test triggered further evaluation.

When evaluated as individual first-stage screens, timed chair stands and grip strength each missed some patients who were classified as frail by the complete index. Chair stands had an area under the receiver operating characteristic curve of 0.982, with a 95% confidence interval of 0.970 to 0.991, and at the selected threshold had sensitivity of 0.918 and specificity of 0.955; nine frail patients were missed. Grip strength had an AUC of 0.920, with a 95% confidence interval of 0.895 to 0.943, sensitivity of 0.955 and specificity of 0.791; five frail patients were missed. Standing balance performed poorly as a stand-alone gate, with an AUC of 0.627, a 95% confidence interval of 0.583 to 0.674, and sensitivity of 0.336 at its selected cutoff. At that cutoff, it missed 73 of 110 frail patients in the component dataset. The investigators therefore reserved balance testing for the complete second-stage LFI assessment instead of using it in the initial triage step.

The combined rule’s zero-miss result reflected complementary capture by the two rapid tests. Of the 112 frail patients, 98 were positive on both chair stands and grip strength, five were positive only on chair stands, and nine were positive only on grip strength. None was negative on both measures. In other words, every patient missed by one component was captured by the other, and a positive result on either test was sufficient for referral. In 2,000 bootstrap resamples, the median sensitivity of the combined rule was 1.000, with both the 2.5th and 97.5th percentiles also at 1.000, and no frail cases were missed in 100% of resamples. An exploratory grid search examined joint cutoffs under a sensitivity constraint of 1.00 and found that the maximum attainable specificity was 0.770, close to the 0.764 of the main strategy. Within this dataset, that result suggests the selected thresholds were near the feasible frontier, although it cannot remove the structural problem of overlap with the reference standard.

Internal split-sample analyses reproduced the same zero-miss pattern. In a temporal validation, cutoffs were derived from the first 400 enrolled patients, including 86 frail patients, and then frozen for the subsequent 204 patients, including 26 frail patients. The later group had sensitivity and negative predictive value of 1.000, specificity of 0.803, a positivity rate of 29.9%, and no missed frailty cases. Applying the full-sample cutoffs to that temporal validation group also produced no missed cases, with 30.9% screening positive. In both directions of an odd-even split, each 302-patient subset also had no missed cases when its own derived thresholds were used. The independently derived cutoffs were similar across subsets: 16.9 to 17.7 seconds for chair stands and 23.2 to 23.4 kilograms for grip strength. These analyses support the within-cohort stability of the pathway, but they are not external validation because all subsets came from the same hospital and recruitment period.

Clinical assessments outside the LFI showed a stepwise gradient across three pathway-defined groups: 376 screen-negative patients, 116 patients who were screen-positive but LFI-negative, and 112 confirmed frail patients. Activities-of-daily-living limitation increased from 25.0% to 34.5% to 75.0% across those groups. High fall risk rose from 26.9% to 43.1% to 70.5%, while nutritional risk increased from 15.4% to 30.2% to 42.9%. Depression and anxiety were available for 455 patients, with denominators of 279, 84 and 92 in the respective groups. Depression was recorded in 21.9%, 22.6% and 33.7% of those patients, while anxiety occurred in 13.3%, 11.9% and 25.0%. Median LFI values also rose from 3.57 to 4.13 to 4.93. These concurrent clinical measures support the interpretation that the three strata differed in clinical burden, but they do not independently validate the LFI definition of frailty.

The pathway also has a clearly defined boundary: it targeted frailty at an LFI score of 4.5 or higher, not the full spectrum of pre-frailty. Among the screen-negative patients, 74.7%, or 281 of 376, were classified as pre-frail, and the highest LFI score among them was 4.45. When the secondary reference threshold of 3.2 or higher was used to combine frailty and pre-frailty, the sensitivity of the either-positive rule fell to 0.442. A negative first-stage result therefore meant that the patient was not classified as frail under the study’s reference standard, not that the patient lacked meaningful functional vulnerability. The study’s boundary analysis supports treating the first stage as a triage process that defers more comprehensive assessment for some patients, rather than as evidence that all clinical concerns had been ruled out.

Several limitations constrain the findings. The single-center, cross-sectional design cannot establish prediction of future outcomes or any longitudinal benefit. No dedicated blinding procedure was documented, and assessors may have known patients’ clinical status. Records did not fully trace the grip-strength dynamometer’s brand, model, nominal resolution or calibration history. Depression and anxiety instruments were not standardized by name, and psychological assessments were available only for a subset. Women numbered 117, and the pooled cutoffs produced a particularly high positivity rate of 78.6% in women, suggesting that sex-specific thresholds may warrant separate evaluation. Exploratory analyses also found lower estimated assessment savings among older patients and those with more severe disease. Liver-disease etiology, fibrosis stage and reason for admission were not systematically retained, limiting subgroup analyses.

Most importantly, the apparent sensitivity and negative predictive value of 1.000 cannot be interpreted as independent diagnostic accuracy because the first-stage measures were embedded in the reference standard. The results show that the simulated pathway had no observed misses among this cohort’s LFI-defined frail patients and could have directed the full index to fewer than four in ten patients. They do not yet establish independent accuracy, clinical safety, improved patient outcomes or time savings in actual nursing workflows. Before routine adoption, the frozen thresholds require prospective, multicenter external validation in independent populations, including larger and more clinically diverse samples of women and patients with chronic liver disease. Implementation studies would also be needed to measure nursing time, workflow burden and patient outcomes.

Subject of Research: Internal evaluation of a two-step bedside frailty-screening pathway in hospitalized adults with chronic liver disease

Article Title: Two‐Step Sequential Screening for Frailty in Patients With Chronic Liver Disease: A Triage Efficiency Study of Liver Frailty Index Components

Article References: Wang, J., Ouyang, S., Zheng, L., Jiang, S., He, N., & Li, L. (2026). Two‐Step Sequential Screening for Frailty in Patients With Chronic Liver Disease: A Triage Efficiency Study of Liver Frailty Index Components. Nursing Open, 13(10), Article e70915. https://doi.org/10.1002/nop2.70915

Image Credits: AI Generated

DOI: 10.1002/nop2.70915

Keywords: frailty screening, chronic liver disease, liver frailty index, nurse-led care, triage efficiency, bedside assessment, grip strength, chair stands, internal validation, clinical workflow, Step, Sequential

The review, led by researchers at King Edward Medical University in Lahore, Pakistan, and the Spinghar Institute of Higher Education in Kabul, Afghanistan, synthesizes evidence from two independent meta-analyses covering more than 3.5 million patients. The larger synthesis of 36 studies found that chronic liver disease raised the odds of death in acute pancreatitis with an odds ratio of 2.53. A subsequent analysis confined to cirrhosis reported a mortality risk ratio of 2.09, falling to 1.94 when only adjusted estimates were pooled. The same analysis found a risk ratio of 2.79 for severe pancreatitis, though notably, the risk of acute kidney injury showed no significant increase, suggesting that not every adverse outcome is uniformly elevated.

The pathophysiological explanation for this dangerous interaction rests on several overlapping mechanisms. Chronic liver disease produces a state of cirrhosis-associated immune dysfunction, in which the body’s ability to clear pathogens is impaired while systemic inflammation persists. The inflammatory cascade in chronic liver disease, characterized by elevated cytokines such as interleukin-6, tumor necrosis factor-alpha, and interleukin-1beta, closely mirrors the immunologic derangements seen in acute pancreatitis. When both conditions coexist, the compounded immune dysfunction can escalate systemic inflammatory response syndrome, leading to multiorgan dysfunction. Furthermore, portal hypertension and systemic vasodilation reduce effective arterial blood volume, exacerbating pancreatic ischemia during pancreatitis and increasing the risk of renal and cardiovascular complications.

Hepatic insufficiency also impairs production of essential proteins such as albumin and coagulation factors, which are critical for maintaining vascular integrity and controlling inflammation. Reduced oncotic pressure, splanchnic vasodilation, and altered hemostatic balance operate together rather than in isolation. Bacterial translocation across a permeable intestinal barrier, an established feature of advanced cirrhosis, provides a plausible route for secondary infection of pancreatic necrosis. The review notes that most of this mechanistic evidence is extrapolated from studies of cirrhosis without pancreatitis or pancreatitis with normal livers, and direct demonstration of liver-pancreas cross-talk in patients carrying both diagnoses remains confined to a small number of animal models and retrospective observational cohorts.

Diagnostic challenges compound the clinical difficulty. Patients with chronic liver disease and acute pancreatitis often present with non-specific overlapping symptoms such as abdominal pain, nausea, vomiting, and jaundice. Hepatic encephalopathy may be confused with sepsis-related delirium from pancreatitis, delaying diagnosis. Ascites, hepatomegaly, and varices can obscure imaging interpretation. The review identifies four distinct clusters of diagnostic uncertainty: analyte failure, in which serum amylase and lipase behave differently in the presence of liver disease; image interpretation failure, in which ascites and altered hepatic architecture degrade the reading; syndrome overlap, in which two conditions generate the same clinical picture; and threshold failure, in which decision thresholds derived from non-cirrhotic populations no longer correspond to the same post-test probability.

The assertion that pancreatic enzymes are unreliable in chronic liver disease warrants scrutiny. The reported reductions in serum amylase and lipase originate largely from small comparative series rather than from studies designed to establish diagnostic accuracy, and the only systematic assessment did not examine cirrhotic patients as a subgroup. Alcohol-related pancreatic exocrine insufficiency, which is common in this group and independently lowers enzyme output, is rarely controlled for. The practical implication is nonetheless reasonable: a normal or only modestly elevated lipase should not by itself exclude acute pancreatitis in a patient with cirrhosis, though this recommendation rests on indirect evidence rather than on formal accuracy data.

Conventional pancreatitis severity scores also underperform in this population for identifiable structural reasons. BISAP assigns points for blood urea nitrogen above 25 mg/dL, impaired mental status, systemic inflammatory response syndrome, age above 60 years, and pleural effusion. Three of these five variables behave abnormally in cirrhosis. Blood urea nitrogen is frequently low despite significant renal impairment because urea synthesis depends on hepatic function, so a cirrhotic patient with genuine renal compromise may score zero on the item intended to capture it. Pleural effusion is common in advanced liver disease from hepatic hydrothorax and therefore loses discriminative value. Altered mental status may reflect hepatic encephalopathy rather than pancreatitis-related organ dysfunction. The net effect is a score that is simultaneously falsely reassuring on one item and falsely alarming on another. APACHE II registers the presence of liver disease as a fixed increment that does not scale with hepatic decompensation, and it draws on physiological variables that are chronically deranged in cirrhosis independently of acute illness, compressing its dynamic range.

Evidence from a single-center retrospective cohort suggests that liver-specific scores outperform conventional pancreatitis scores in this population. MELD, calculated from bilirubin, creatinine, and the international normalized ratio, is continuous, objective, and free of subjective components, and creatinine captures the renal dysfunction that drives much of the mortality in severe pancreatitis. Its weakness is that all three components can be perturbed by pancreatitis itself rather than by liver disease. Child-Pugh includes ascites and encephalopathy, which are more specific to chronic liver disease, but it depends on subjective grading and has a ceiling effect. The comparative evidence is thin, coming from a single retrospective cohort that has not been replicated prospectively. A reasonable interim position is that liver-specific and pancreatitis-specific scores should be calculated in parallel rather than one substituted for the other.

Management of these patients requires modifications across nearly every domain of care. The hemodynamic state in cirrhosis is characterized by low systemic vascular resistance, high cardiac output, and low effective blood volume, narrowing the margin for safe fluid resuscitation. The WATERFALL trial, which randomized patients to aggressive or moderate goal-directed fluid therapy, found no reduction in disease progression and a substantially higher incidence of fluid overload in the aggressive arm, supporting moderate resuscitation. However, the trial did not report cirrhosis as a stratifying variable, so the applicability of its thresholds to patients with a hyperdynamic circulation is inferred rather than demonstrated. The review argues that resuscitation in this group should be guided by dynamic measures of fluid responsiveness and serial lactate rather than by fixed pressure and urine output targets, though no trial has tested this. Hypoalbuminemia is common in cirrhosis and has been associated with increased mortality in severe pancreatitis, with one retrospective cohort suggesting that albumin infusion in the first week was associated with lower mortality rates.

Nutritional support represents an area where the two disease-specific literatures conflict most directly. In pancreatitis, the PYTHON trial showed that early nasoenteric tube feeding within 24 hours was not superior to an oral diet started at 72 hours, and current guidance favors early oral intake as tolerated. In cirrhosis, by contrast, European guidance advises avoiding prolonged fasting, with a protein intake of 1.2 to 1.5 g/kg/day and late evening carbohydrate supplementation, because cirrhotic patients enter a catabolic state after relatively short periods without food and because sarcopenia is an independent predictor of mortality. A cirrhotic patient kept nil by mouth for 72 hours in accordance with pancreatitis practice may therefore accrue nutritional harm that the pancreatitis literature does not measure. The reasonable synthesis is that the permissive fasting window should be shortened in patients with cirrhosis, that enteral rather than parenteral routes should be preferred, and that protein should not be restricted in the absence of overt encephalopathy.

Procedural decisions also require modification. The APEC trial supported a restrictive approach to ERCP, reserving it for patients with cholangitis or persistent cholestasis. This restrictive position is more strongly justified in cirrhosis, because pooled data from 24 studies and more than 28,000 patients show that cirrhosis raises the overall risk of post-ERCP adverse events, with the clearest excess in bleeding, and that complication rates rise with Child-Pugh class. The prolonged international normalized ratio of cirrhosis reflects a rebalanced rather than a hypocoagulable state, and correction with fresh frozen plasma before procedures increases volume load without reliably reducing bleeding. For pancreatic necrosis, the step-up approach is amplified in cirrhosis, where open necrosectomy carries added hazards of bleeding from abdominal wall collaterals, difficult wound healing, ascitic leak, and postoperative hepatic decompensation.

Acute-on-chronic liver failure, defined as acute decompensation of cirrhosis accompanied by organ failure, is an under-recognized consequence of pancreatitis in cirrhotic patients. In one retrospective cohort, 44 percent of patients with pancreatitis and liver cirrhosis developed this syndrome. The clinical importance lies in prognosis and in the timing of escalation, since the CLIF-C organ failure scores provide dynamic prognostic information, and response to treatment assessed at days three to seven is more informative than admission severity alone. A patient whose grade does not improve over that interval has a poor outlook with continued supportive care and should prompt early discussion of transplant candidacy. The review emphasizes that this framework has been developed and validated for precipitants such as bacterial infection and variceal bleeding, and that its behavior when the precipitant is pancreatitis has not been formally studied.

The etiology of liver disease further modifies pancreatitis severity, though the evidence supporting etiology-specific effects is weaker than that supporting the overall association. Alcohol-related disease is where the association is most readily observed and hardest to interpret, because alcohol independently causes recurrent and necrotizing pancreatitis, so any cohort assembled based on alcoholic cirrhosis is enriched for severe pancreatitis before liver disease is considered. Effect sizes reported in alcohol-related cohorts should be treated as upper bounds rather than as best estimates. Viral hepatitis presents the opposite problem: confounding by shared etiology is minimal, making it the cleanest available exposure scientifically, yet it is the one least often reported separately. Metabolic dysfunction-associated steatotic liver disease is the largest group in the pooled literature, with 24 of 36 studies in the larger meta-analysis concerning steatotic disease against 12 concerning cirrhosis, creating a problem of representation that is easy to miss. Combining these exposures under one label is the single most consequential definitional problem in this field.

The review’s authors are candid about the limitations of the evidence base. Almost everything rests on retrospective observational data of level III to IV quality, drawn from heterogeneously defined populations with inconsistent adjustment for confounding. The direction of the association is secure; its magnitude is not. Publication bias has been formally tested and was negative, though several outcomes were pooled from fewer than ten studies, below which such tests have very low power. Outcome reporting bias is the more plausible mechanism, illustrated by the fact that the larger synthesis could not pool infection data at all because definitions varied and reporting was inconsistent. An outcome that cannot be pooled cannot be tested for bias.

Four research priorities emerge from the review. A prospective multicenter cohort using a standardized definition of chronic liver disease, stratified by Child-Pugh class, with severity adjudicated in a way that separates hepatic from pancreatic organ failure, would resolve much of the current uncertainty about effect size. Prospective validation of MELD and Child-Pugh against BISAP and APACHE II in this population would address the most immediately actionable clinical question. A trial of fluid resuscitation strategy in cirrhotic patients with pancreatitis, using dynamic measures of fluid responsiveness rather than fixed pressure targets, is both feasible and needed. Finally, the natural history of pancreatitis as a precipitant of acute-on-chronic liver failure warrants dedicated study. Until such data exist, the management of these patients will continue to rest on physiological reasoning applied to evidence generated in other populations, and clinicians should be explicit with themselves about that when making decisions at the bedside.

Subject of Research: Chronic liver disease amplifies the severity and mortality of acute pancreatitis through overlapping inflammatory, hemodynamic, and metabolic mechanisms

Article Title: Chronic liver disease impacting the severity of acute pancreatitis: a detailed narrative review of the literature

Article References: Basit, A., Usman, M. A., Ali, S. M., & Basil, A. M. (2026). Chronic liver disease impacting the severity of acute pancreatitis: a detailed narrative review of the literature. Frontiers in Gastroenterology, 5, Article 1921741. https://doi.org/10.3389/fgstr.2026.1921741

Image Credits: AI Generated

DOI: 10.3389/fgstr.2026.1921741

Keywords: acute pancreatitis, chronic liver disease, cirrhosis, inflammation, organ failure, severity scores, MELD, Child-Pugh, fluid resuscitation, nutrition, Chronic, liver

The study, published in Frontiers in Gastroenterology, took an unusual two-pronged approach known as triangulation, pairing a Mendelian randomization analysis of large genetic datasets with a retrospective clinical study of patients whose portal pressure was measured directly. The logic behind triangulation is simple but powerful: no single observational study can fully rule out confounding, so researchers seek multiple lines of evidence that rely on different assumptions. If independent methods converge on the same answer, the conclusion becomes far harder to dismiss as an artifact of bias.

Mendelian randomization exploits a quirk of biology: genes are randomly allocated at conception and remain fixed throughout life. By using genetic variants that predict dietary fat intake as instruments, researchers can approximate a randomized trial of lifelong eating habits without actually assigning diets. Because the genes are inherited randomly, they are largely immune to the confounding factors that plague ordinary nutrition studies, such as obesity, insulin resistance, or the tendency of advanced liver disease itself to change what people eat. The method rests on three assumptions: the genetic variants must be strongly associated with the exposure, must not be linked to confounders, and must influence the outcome only through the exposure.

In practice, the team drew on genome-wide association study data covering 268,922 people of European ancestry, selecting 18 independent single nucleotide polymorphisms associated with fat intake as a percentage of total energy consumption. These instruments were strong by conventional standards, with a mean F-statistic of 34.2 against the threshold of 10 usually required, though together they explained only 2.8 percent of the variation in dietary fat. The primary analysis, an inverse variance weighted method, found that each standard deviation increase in genetically predicted fat intake was associated with 28 percent higher odds of portal hypertension, an odds ratio of 1.28 with a 95 percent confidence interval of 1.15 to 1.42 and a p-value of 1.0 times ten to the minus five.

Crucially, the association held up across every complementary method the team applied. The weighted median estimator, which remains valid even if up to half of the instruments are faulty, produced an odds ratio of 1.23. MR-Egger regression, designed to detect directional pleiotropy, where variants affect the outcome through pathways other than the exposure, yielded 1.35, and its intercept test showed no evidence of such pleiotropy. Cochran’s Q statistic found no significant heterogeneity among the SNP estimates, and the MR-PRESSO outlier-detection procedure identified no pleiotropic outliers, with the outlier-corrected estimate virtually identical to the original. A leave-one-out analysis confirmed that no single genetic variant was driving the result, and a Steiger directionality test verified that the causal arrow runs from diet to disease rather than the reverse. An independent FinnGen analysis of nearly 400,000 Finns, using liver cirrhosis as a surrogate endpoint with zero participant overlap, replicated the direction and significance of the effect.

The clinical arm of the study grounded these genetic findings in measurable physiology. The researchers retrospectively studied 72 patients with chronic liver disease who underwent hepatic venous pressure gradient, or HVPG, measurement at a tertiary hepatology center between 2021 and 2023. HVPG, the difference between wedged and free hepatic venous pressures, is the gold standard for assessing portal pressure, with values above 5 mmHg defining portal hypertension and values at or above 10 mmHg defining clinically significant disease. Dietary intake was assessed with a validated 168-item food frequency questionnaire administered by trained staff, and a high-fat diet score from 0 to 10 was calculated from consumption of red and processed meats, high-fat dairy, fried foods, cooking oils, and nuts and seeds.

The correlation was striking. The high-fat diet score correlated with HVPG at r = 0.700, and patients in the highest tertile of fat intake had a mean HVPG of 14.53 mmHg, compared with 12.29 mmHg in the moderate group and 9.37 mmHg in the low-fat group, a gap of roughly 5 mmHg between the extremes. The clinical stakes of that gap are considerable, because each 1 mmHg increase in HVPG is associated with approximately 10 to 15 percent higher risk of variceal bleeding, and even reductions of 2 to 3 mmHg are considered clinically meaningful. Nearly 94 percent of the high-fat diet group had clinically significant portal hypertension, versus only about 42 percent of the low-fat group.

Importantly, the association survived statistical adjustment. In a multivariate linear regression controlling for age, sex, BMI, bilirubin, albumin, and platelet count, each one-point increase in the high-fat diet score predicted a 0.85 mmHg increase in HVPG, and a partial correlation adjusting for BMI alone remained significant. That finding suggests dietary composition matters beyond its effect on body weight, consistent with emerging evidence that saturated and trans fats can exert direct hepatotoxic effects independent of overall adiposity. The regression model explained 62.3 percent of the variance in HVPG, and cross-validation and bootstrap correction confirmed it retained good predictive performance despite the modest sample size.

The authors stress that they did not directly test mechanisms, but several plausible biological pathways could connect fatty diets to raised portal pressure, all drawn from prior literature and acknowledged as speculative. Hepatic steatosis, the accumulation of fat inside liver cells, may increase intrahepatic vascular resistance by compressing sinusoids and reducing vascular compliance. Lipotoxicity from saturated fatty acids can trigger oxidative stress, endoplasmic reticulum stress, and activation of hepatic stellate cells, the cells that drive fibrosis. High-fat diets may also disrupt the gut microbiome and increase intestinal permeability, flooding the liver with bacterial endotoxin and fueling inflammation, while the associated insulin resistance can raise hepatic vascular tone by impairing nitric oxide signaling.

The study has real limitations, and the researchers are candid about them. Mendelian randomization captures the effect of lifelong genetic predisposition, which may not translate directly into the benefits of moderate dietary changes adopted in adulthood. The genetic analysis was restricted to people of European ancestry, the dietary data relied on self-reported questionnaires, and the clinical cohort was small and drawn from a single center with a retrospective design. The diet score also did not distinguish saturated from unsaturated fats. Even so, the convergence of genetic and clinical evidence on the same conclusion gives the finding unusual weight, and the authors argue it provides a rationale for testing dietary fat reduction as a potential adjunctive strategy for managing portal hypertension, pending confirmation in prospective intervention trials. For now, the message is a cautious one: what lands on the plate may help determine the pressure inside the portal vein.

Subject of Research: Causal relationship between high-fat diet and portal hypertension assessed by Mendelian randomization and clinical HVPG measurement

Article Title: High-fat diet and portal hypertension: a triangulation approach combining Mendelian randomization with retrospective clinical analysis

Article References: Xu, Y., Yang, S., Li, Y., Han, Q., & Wang, W. (2026). High-fat diet and portal hypertension: a triangulation approach combining Mendelian randomization with retrospective clinical analysis. Frontiers in Gastroenterology, 5, Article 1927449. https://doi.org/10.3389/fgstr.2026.1927449

Image Credits: AI Generated

DOI: 10.3389/fgstr.2026.1927449

Keywords: portal hypertension, high-fat diet, Mendelian randomization, hepatic venous pressure gradient, liver disease, causal inference, NAFLD, cirrhosis, GWAS, dietary fat, triangulation, hepatology

The anatomical logic behind this connection is elegant. The liver receives the entire venous outflow of the gut through the portal circulation, meaning it is continuously bathed in microbial products, metabolites and dietary antigens. In return, the liver secretes bile acids and other bioactive mediators into the intestine that directly shape which microbial species can thrive there. This bidirectional communication network, known as the gut–liver axis, places the immune system at its centre, tasked with maintaining a delicate equilibrium between tolerance toward commensal bacteria and robust defence against pathogens. T cells are uniquely positioned within this axis because they can recognize an extraordinarily broad spectrum of microbial antigens, and their differentiation, function and plasticity are in turn profoundly sculpted by microbial cues.

The review details how specific gut microbes direct the fate of distinct T helper subsets with remarkable precision. Segmented filamentous bacteria, for example, are a classical inducer of Th17 cells: their adhesion to intestinal epithelial cells triggers secretion of serum amyloid A, which acts on CD11c-positive cells to potentiate Th17 differentiation, amplified by a positive feedback loop involving interleukin-1β. More recently, the ubiquitous commensal Alcaligenes faecalis was shown to induce intestinal Th17 cells through the Trim21–Fbxw7 axis, and even the fungus Candida albicans can promote Th17 accumulation in the colon. Bacterial metabolites add a second layer of control. Short-chain fatty acids such as acetate, propionate and butyrate, secondary bile acids including deoxycholic acid and isolithocholic acid, and tryptophan-derived indoles all modulate Th17, Th1 and regulatory T cell programmes, often through inhibition of histone deacetylases or direct engagement of transcription factors such as RORγt.

Regulatory T cells, which express the transcription factor FOXP3 and enforce immune tolerance, are equally dependent on microbial instruction. Genera including Clostridium, Bacteroides, Bifidobacterium and Helicobacter promote colonic Treg induction, while Akkermansia muciniphila alleviates colonic inflammation by expanding RORγt-positive Treg responses. Butyrate and propionate enhance Foxp3 expression through histone acetylation at conserved non-coding sequences, and specific bile acid metabolites such as 3β-hydroxydeoxycholic acid promote Treg generation. Beyond conventional T cells, the review highlights innate-like lymphocytes with deep microbial entanglement: mucosal-associated invariant T cells depend on early-life exposure to riboflavin-synthesizing commensals, which produce the potent antigen 5-OP-RU, while hepatic natural killer T cells are regulated by microbiota-driven bile acid metabolism that controls CXCL16 expression in liver sinusoidal endothelial cells. Gamma-delta T cells, abundant in both liver and intestine, respond to microbial lipid antigens presented by hepatocytes and modulate their interleukin-17 output according to bacterial load.

Crucially, the communication is not one-way. T cells themselves reshape the microbial ecosystem. Microbiota-derived extracellular ATP constrains T follicular helper cell function through the P2X7 receptor, limiting secretory IgA production; in P2X7-deficient mice, excessive IgA disrupts microbial composition and drives metabolic dysregulation. Gamma-delta T cell-deficient mice display altered microbiota composition that feeds back into immune dysregulation, and studies of NKT cell-deficient animals have reported shifts in commensal communities, although recent work using littermate controls suggests maternal transmission and caging conditions may matter more than genotype. T cell plasticity further complicates the picture: Th17 cells can convert toward Th1 or T follicular helper phenotypes, and while the initial conversion of CD8-positive to CD4-positive T cells can occur without microbes, their subsequent homing and expansion in the gut critically depend on microbial signals.

When this finely balanced system fails, the consequences for the liver can be severe. The review describes how disruption of the intestinal barrier, the so-called leaky gut, permits bacteria, toxins and microbial antigens to translocate into the portal vein and systemic circulation. Molecular mimicry provides one mechanistic bridge: the pyruvate dehydrogenase complex E2 of Escherichia coli cross-reacts with its human counterpart at the T cell receptor level, contributing to primary biliary cholangitis, while cross-reactivity between microbial antigens and host components has been implicated in primary sclerosing cholangitis and autoimmune hepatitis. Gut dysbiosis, characterized by reduced microbial diversity, overgrowth of pathogenic taxa and depletion of beneficial commensals, accompanies virtually every form of chronic liver disease, and advanced cirrhosis additionally enriches virulence factors and antimicrobial resistance genes within the microbiome.

Disease-specific examples illustrate the diversity of these pathogenic axes. In autoimmune hepatitis, the pathobiont Enterococcus gallinarum translocates to the liver, where its DNA has been detected in patients and where it drives Th17 responses and autoantibody production in mice; conversely, the microbial metabolite indole-3-carboxaldehyde ameliorates immune-mediated hepatitis by activating the aryl hydrocarbon receptor in T cells. In primary sclerosing cholangitis, Klebsiella pneumoniae with strain-specific epithelial pore-forming capacity breaches the intestinal barrier and provokes robust hepatic Th17 responses, while translocated Lactobacillus gasseri induces IL-17A production by gamma-delta T cells in cholestatic models. In alcohol-associated liver disease, ethanol promotes fungal dysbiosis and generates Candida albicans-specific Th17 cells that migrate to the liver and exacerbate injury through IL-17 signalling on Kupffer cells, while peripheral MAIT cells become depleted and hyperactivated through heightened exposure to translocated bacterial products.

Metabolic dysfunction-associated steatotic liver disease, which affects approximately 38 percent of the global adult population, adds yet another dimension. High-fat diet models show depletion of protective intestinal Th17 cells, promoting microbial migration that accelerates disease, while microbiota-derived lipid antigens presented by hepatocytes via CD1d stimulate hepatic IL-17-producing gamma-delta T cells. Faecal bacterial extracts from patients with MASLD-related hepatocellular carcinoma induce immunosuppressive phenotypes ex vivo, expanding Treg cells and attenuating CD8-positive T cell function in a short-chain fatty acid-dependent manner. In chronic hepatitis B, bacterial extracts from non-cirrhotic patients promote Th17 expansion whereas those from cirrhotic patients inhibit Th1 cells, and strikingly, a probiotic consortium of Bifidobacterium longum, Enterococcus faecalis and Lactobacillus acidophilus, together with its metabolite spermidine, suppresses HBV replication by augmenting IFNγ-positive CD4-positive T cell immunity.

These mechanistic insights are now feeding into a therapeutic pipeline that targets both sides of the axis. Microbiota-directed interventions include probiotics such as Lactobacillus acidophilus, which attenuated cholestatic liver damage in mice and improved liver function in cholestatic patients, and Lactobacillus rhamnosus GG, which alleviated liver injury in moderate alcohol-associated hepatitis. Prebiotics such as inulin and camu-camu have shown benefits in metabolic liver disease, although inulin failed to improve early alcoholic liver injury despite reshaping the microbiome. Faecal microbiota transplantation increased bacterial diversity and reduced alkaline phosphatase in primary sclerosing cholangitis and restored intestinal permeability in MASLD, though it did not improve hepatic fat fraction or insulin resistance. On the T cell side, chimeric antigen receptor T cell therapy eliminated pathogenic PD-1-positive CD8-positive T cells that drive hepatocyte pyroptosis in autoimmune liver disease models, autologous Treg infusion significantly reduced liver enzymes in a patient with refractory PSC/UC, and low-dose interleukin-2 therapy that selectively expands Tregs has shown early promise.

The authors caution that the gut–liver–immune network is dynamic and bidirectional, meaning that targeting a single component may trigger unanticipated cascades; indeed, the efficacy of CAR-T therapy itself can be modulated by the intestinal microbiota. They argue that future progress will require patient-stratified approaches, deeper elucidation of the specific microbial taxa and immunological mechanisms underlying each disease, and clinical validation of candidate targets. If that integration of microbiome science with translational immunology succeeds, the microbial cues that currently fuel chronic liver disease could be repurposed as precise levers for its prevention and treatment, opening a genuinely new therapeutic frontier for conditions that have long defied conventional intervention.

Subject of Research: Bidirectional interactions between gut microbiota and T cell immunity in the progression of chronic liver disease

Article Title: Microbial cues and T cell immunity: deciphering their interactions in chronic liver disease

Article References: Liu, Y., Yu, B., Liu, Q., Ma, X., & Tang, R. (2026). Microbial cues and T cell immunity: deciphering their interactions in chronic liver disease. Experimental & Molecular Medicine. https://doi.org/10.1038/s12276-026-01831-y

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01831-y

Keywords: gut-liver axis, gut microbiota, T cells, chronic liver disease, Th17 cells, regulatory T cells, autoimmune liver disease, alcohol-associated liver disease, MASLD, viral hepatitis, microbial metabolites, immunotherapy

The scale of the resource is what sets it apart. Most previous single-cell RNA sequencing studies of human liver pooled relatively small numbers of cells from limited patient cohorts, which made it hard to resolve subtle transcriptional states relevant to disease. The new atlas integrates seven published studies into a single reference containing 649,295 cells drawn from 77 donors—42 with healthy livers and 35 with chronic liver disease, balanced across 38 males and 39 females. After rigorous quality control, iterative subclustering and manual annotation, the researchers organized the data into three hierarchical levels: 16 broad cell lineages, 34 intermediate cell types and, at the finest resolution, 125 transcriptionally distinct cellular states. The atlas even captured rare residents of the liver, including neurons, mast cells, basophils, neutrophils and hematopoietic progenitor cells, which individual studies had rarely described. An interactive web browser allows any researcher to query the gene expression profiles.

The analytical centerpiece concerns macrophages, the scavenger immune cells that both fuel and resolve fibrosis. Within 81,577 nonproliferating mononuclear phagocytes, the team distinguished tissue monocytes, conventional dendritic cells, resident Kupffer cells and, crucially, two separate populations of so-called scar-associated macrophages, or SAMacs—cells marked by the proteins TREM2, CD9, CD63 and SPP1 that previous work had implicated in activating the scar-producing myofibroblasts of the liver. Differential abundance testing with the Milo algorithm showed that both SAMac populations expand in diseased livers, but with a telling difference: SAMac2 expanded consistently across every etiology of chronic liver disease, whereas SAMac1 expansion was most pronounced in the biliary disorders primary biliary cholangitis and primary sclerosing cholangitis.

Why does splitting SAMacs into two matter? Because the field has been stuck in a contradiction. Some studies painted TREM2-positive scar macrophages as fibrosis drivers; others found that TREM2 and the SAMac molecule SPP1 actually carry anti-inflammatory and antifibrotic properties, promoting scar resolution. The new data dissolve the paradox by showing that the two SAMac populations are transcriptionally almost opposite. Differential expression analysis, run with a statistical hurdle model and Bonferroni correction, flagged 903 genes enriched in SAMac1 and 1,176 in SAMac2. SAMac1 expressed GPNMB along with a suite of reparative factors—MMP9, IL10, GDF15, CD36 and PPARG—resembling the lipid-associated macrophages described in mouse and human fatty tissue. SAMac2, by contrast, lit up with pro-inflammatory and pro-fibrotic mediators: IL1B, TNF, IL18, the inflammasome component NLRP3, AREG and PDGFB, plus the scavenger receptors OLR1 and CLEC5A. Flow cytometry confirmed expansion of TREM2-positive, OLR1-positive macrophages in diseased human livers, and immunofluorescence placed OLR1-positive CD68-positive cells precisely within fibrotic tissue.

Spatial context came from a 36-plex antibody panel run on the PhenoCycler-Fusion platform across 46 patient liver samples, spanning healthy tissue and explants or biopsies from metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-related liver disease, PBC and PSC. Computational neighborhood analysis identified three cellular niches, one of them a fibrotic niche packed with fibroinflammatory cells and dense fibrillar collagen deposition that expanded dramatically in disease. Both OLR1-positive and GPNMB-positive macrophages preferentially accumulated inside that niche, yet they remained largely distinct from one another—occasional double-positive cells existed, but the two markers mostly labeled separate cells, mirroring the single-cell data and confirming genuine macrophage heterogeneity at the site of scarring.

The clinical stakes became clear when the team turned to outcome data. In liver needle biopsies from MASLD patients, SAMacs expanded and upregulated OLR1, which stayed macrophage-specific. Then, mining the SteatoSITE multimodal database of 632 histologically staged MASLD cases, the researchers found that hepatic OLR1 expression correlated positively with fibrosis stage and with other fibroinflammatory genes, and negatively with markers of homeostatic Kupffer cells and sinusoidal endothelial cells. Deconvolution of bulk RNA-sequencing data using the single-cell reference showed both SAMac populations rising with fibrosis stage, a pattern replicated in independent cohorts of MASLD, PSC, ARLD and PBC patients. Most strikingly, in the longitudinal SteatoSITE cohort, high OLR1 expression and high estimated SAMac2 abundance were both associated with increased all-cause mortality and faster progression to hepatic decompensation—the point at which a scarred liver stops coping.

Cross-species work strengthened the case. In mouse models of fibrosis induced by carbon tetrachloride, bile duct ligation and a choline-deficient high-fat diet, the team found the same two Trem2-positive SAMac subpopulations, with the Olr1-positive counterpart again enriched for inflammatory genes including Il1b and Nlrp3. Both populations expanded during active injury and returned to baseline once injury ceased, tracking fibrogenic activity in time as well as space. Flow cytometry showed that Olr1-positive SAMacs produced more interleukin-1 beta than their CD319-positive SAMac1 counterparts. Bone-marrow chimera experiments established that both subpopulations arise from circulating monocytes rather than resident Kupffer cells. Single-cell ATAC-sequencing added a chromatin dimension: Olr1-positive SAMac2 carried open chromatin enriched for pro-inflammatory transcription factor motifs—Fos, Jun, NF-kB and Rel family members—while SAMac1 showed motifs linked to interferon responses and regulatory factors, indicating the two states are epigenetically primed for different jobs.

Ligand-receptor modeling with the LIANA and Tensor-cell2cell frameworks then predicted how each SAMac population talks to the mesenchymal cells that manufacture collagen. SAMac1’s outgoing signal repertoire contained recognized antifibrotic factors such as HGF, IGF1, MMP9 and GDF15. SAMac2’s contained TNF, TGFB1, IL1B, IL18, complement C3 and PDGFB—mediators associated with promoting fibrogenesis. Functional tests followed. Conditioned media from human monocyte-derived macrophages with OLR1 knocked down by siRNA were less able to induce collagen gene expression in LX2 stellate cells, and treatment with MEDI6570, a clinically tested OLR1-blocking antibody, similarly dampened fibrillar collagen expression. In a three-dimensional multilineage spheroid model of MASH—primary hepatocytes, macrophages and stellate cells challenged with lipotoxic free fatty acids—OLR1 knockdown reduced fibrogenic activity and abolished fibrillar collagen protein production. The team also showed that a chronic inflammatory stimulus cocktail (TNF, prostaglandin E2 and Pam3CSK4) pushed macrophages toward the SAMac2 program, whereas fatty acids and glucocorticoids pushed toward the SAMac1-like state.

The therapeutic implication is unusually concrete, because OLR1—also known as LOX-1, a class E scavenger receptor—already has a drug-development history in cardiovascular medicine, where it has been implicated in atherosclerosis, cardiac fibrosis and cancer biology. MEDI6570 has been administered to patients in phase 1 and phase 2 trials, raising the prospect of repurposing it, or developing small-molecule OLR1 inhibitors, for liver disease. The authors caution that much remains to be learned: the activating ligands of OLR1 in the injured liver, whether macrophages can switch between the SAMac1 and SAMac2 states, and whether OLR1 can serve as a predictive biomarker all require further study. They also note that hepatocytes and stellate cells are better captured by single-nucleus approaches, and that candidate targets from single-cell studies must be validated in independent, histologically staged biopsy cohorts—as OLR1-positive SAMacs were here. Still, by resolving the heterogeneity that had made scar macrophages such a confusing target, the atlas converts a paradox into a plan: spare the reparative macrophages, silence the inflammatory ones, and perhaps finally slow the scarring that ends so many livers.

Subject of Research: Single-cell transcriptomic identification of OLR1-positive scar-associated macrophages as a therapeutic target in chronic liver disease fibrosis

Article Title: A human single-cell atlas identifies OLR1+ scar-associated macrophages as a potential therapeutic target for chronic liver disease

Article References: Papachristoforou, E., Kong, K., Colella, F., Tam, J., Luft, J., Parhar, R., Liang, Y., McCafferty-Brown, A., Finney, G., Rao, K., Ravichandar, J. D., Sutherland, E. F., Veizades, S., Grzelka, M., Qiu, P. K., Asif, A., Battle, I., Hammer, M., Kuschnereit, T., … Ramachandran, P. (2026). A human single-cell atlas identifies OLR1+ scar-associated macrophages as a potential therapeutic target for chronic liver disease. Nature Genetics, 58(10), 2550-2565. https://doi.org/10.1038/s41588-026-02774-w

Image Credits: AI Generated

DOI: 10.1038/s41588-026-02774-w

Keywords: single-cell RNA sequencing, liver fibrosis, macrophages, OLR1, chronic liver disease, scar-associated macrophages, TREM2, MASLD, spatial proteomics, antifibrotic therapy, Nature Genetics, liver atlas

The research, conducted by a team at The Third People’s Hospital of Shenzhen in Guangdong Province, China, enrolled 92 children aged zero to fourteen years who had been diagnosed with chronic liver disease. Chronic liver disease in children, which encompasses conditions such as biliary atresia, metabolic liver disorders, and cirrhosis of various origins, imposes a heavy physical toll on patients and a profound burden on families. Unlike acute illnesses that resolve with a single course of treatment, chronic liver disease demands sustained management, frequent monitoring of liver function, careful nutritional support, and in severe cases, preparation for transplantation. The period immediately after discharge, when families must translate hospital-based care into home-based routines, has long been recognized as a point of vulnerability where complications can emerge and readmissions become more likely.

The study’s central innovation lies in its systematic approach to building the intervention. Rather than designing a care program from assumptions alone, the research team integrated findings from questionnaire surveys, qualitative interviews with families, a structured review of the existing literature, and consultation with clinical experts. This multi-method development process allowed the program to be tailored to the actual needs and concerns reported by caregivers, and critically, to be adjusted according to each child’s individual level of discharge readiness. Discharge readiness, as a concept, refers to the degree to which a patient and family are prepared, both practically and psychologically, to manage care outside the hospital. It encompasses knowledge of the condition, technical skills such as medication administration, emotional preparedness, and the availability of expected support resources.

The study employed a comparative design in which children were assigned to an intervention group receiving the continuity of care program and a control group receiving standard discharge procedures. At baseline, the two groups were well matched: the researchers report no significant differences in demographic or clinical characteristics, nor in levels of social support available to the families. This methodological rigor matters because social support is one of the strongest confounders in studies of post-discharge outcomes. Families with robust networks of relatives, friends, and community resources tend to fare better regardless of the formal care they receive, so demonstrating equivalence at baseline strengthens the argument that any observed differences in outcomes can be attributed to the intervention itself.

The results were striking. Children in the intervention group demonstrated significantly higher discharge readiness across all measured dimensions compared with those in the control group, with differences reaching statistical significance at p less than 0.001. This threshold indicates that the probability of such a large difference arising by chance is less than one in a thousand, a level of statistical confidence that lends considerable weight to the finding. The intervention group also received higher-quality discharge guidance scores, suggesting that the program improved not only the preparedness of families but also the performance of the clinical staff responsible for preparing them for the transition home.

Beyond the technical measures of readiness and guidance quality, the program appeared to deliver meaningful psychological benefits. Anxiety scores were significantly lower in the intervention group, with differences reaching significance at p less than 0.05. This finding deserves particular attention because anxiety among caregivers of children with chronic illness is not a peripheral concern. Elevated parental anxiety has been linked to impaired caregiving behaviors, difficulty retaining medical instructions, and worse health outcomes for the child. A parent who is overwhelmed by worry may hesitate to administer medications correctly, may miss early signs of decompensation, or may avoid seeking timely medical help. By reducing anxiety, the continuity of care program may have created a virtuous cycle in which calmer, better-prepared caregivers provide more effective home care, which in turn reinforces their confidence and competence.

The architecture of a continuity of care program of this kind typically involves several coordinated elements that extend the hospital’s reach into the home. While the source study describes the program as being tailored to discharge readiness levels, the underlying logic is that families at different stages of preparedness require different intensities and types of support. A family that scores low on readiness might need intensive education sessions, hands-on demonstrations of care techniques, and frequent telephone follow-up in the first days after discharge, whereas a family that is already well prepared might benefit primarily from scheduled check-ins and access to a consultation channel for questions as they arise. This stratified approach stands in contrast to one-size-fits-all discharge instructions, which often overwhelm some families while leaving others with unmet informational needs.

The theoretical case for such programs rests on a well-established observation in health services research: the transition from hospital to home is a period of heightened risk, particularly for patients with complex chronic conditions. Medication errors, missed follow-up appointments, and failure to recognize deteriorating symptoms cluster in the days and weeks after discharge. For children with chronic liver disease, the stakes are especially high because hepatic decompensation can progress rapidly, and because many of these children are on complicated medication regimens that may include immunosuppressants, diuretics, or nutritional supplements whose dosing requires careful adjustment. A structured continuity of care program acts as a bridge across this risky interval, ensuring that the expertise of the hospital team remains accessible while families gradually build the self-care abilities the study’s authors highlight as a key intended outcome.

The study’s conclusions extend beyond the immediate endpoints of readiness and anxiety. The authors suggest that the program may promote the development of self-care abilities among both children and their caregivers, enhance satisfaction with nursing care, and ultimately improve quality of life. These are ambitious claims, and the study’s design, which measured readiness, guidance quality, and anxiety directly, supports the first two more firmly than the longer-term quality-of-life outcomes, which the authors frame as potential downstream benefits. Still, the logic of the pathway is coherent: families who leave the hospital feeling prepared and supported are better positioned to manage daily care, maintain follow-up schedules, and sustain the child’s health over time, all of which contribute to a better lived experience with a chronic condition.

The research carries practical implications for pediatric hepatology services far beyond Shenzhen. Hospitals caring for children with chronic liver disease could adopt the program’s development methodology, combining quantitative surveys, qualitative family interviews, literature synthesis, and expert consultation, to build discharge support systems matched to their own patient populations. The finding that discharge readiness can be measurably improved across all dimensions suggests that readiness is not a fixed family trait but a modifiable clinical target, something that skilled nursing intervention can move. As health systems worldwide grapple with rising rates of chronic disease in children and pressure to reduce readmissions, this study offers a concrete, evidence-based template: assess each family’s readiness before discharge, tailor the continuity of care program to that readiness level, and maintain structured contact after the child goes home. For the families navigating the daily realities of childhood liver disease, that structured support may transform the daunting journey from hospital ward to home into a managed, supported transition rather than a leap into the unknown.

Subject of Research: A discharge readiness-based continuity of care program for children with chronic liver disease

Article Title: Efficacy of a continuity of care program based on discharge readiness for children with chronic liver disease

Article References: Liao, Q.-H., Fu, K.-H., Ma, S., Zhang, S.-Y., Ning, X.-L., Hu, X.-Q., Sun, L.-L., & Xiao, W.-L. (2026). Efficacy of a continuity of care program based on discharge readiness for children with chronic liver disease. BMC Health Services Research. https://doi.org/10.1186/s12913-026-15630-8

Image Credits: AI Generated

DOI: 10.1186/s12913-026-15630-8

Keywords: chronic liver disease, pediatrics, discharge readiness, continuity of care, nursing, caregivers, anxiety, health services research, patient transition, hospital discharge, self-care, quality of life

The study team, led by Reza Zabihi of the Student Research Committee at Babol University of Medical Sciences together with colleagues from the university’s departments of internal medicine, social determinants of health, and infectious diseases research, designed the investigation as a matched-style comparison rather than a simple survey of liver patients. They enrolled 37 hospitalized COVID-19 patients with documented pre-existing chronic liver disease and selected 77 comparison patients who were hospitalized with confirmed COVID-19 but had neither chronic liver disease nor other documented chronic comorbidities. This deliberate selection of a relatively clean comparison group is analytically important: by stripping away diabetes, cardiovascular disease, and other common confounders, the researchers sought to isolate the contribution of liver pathology itself to COVID-19 outcomes, rather than the contribution of multimorbidity in general.

The demographic profiles of the two groups were closely aligned. The mean age in the chronic liver disease group was 57.03 years with a standard deviation of 13.85, while the comparison group averaged 55.05 years with a standard deviation of 14.42, a difference that did not reach statistical significance. This age matching matters because age is among the strongest predictors of severe COVID-19, and any meaningful gap in age distribution could have distorted the apparent effect of liver disease. Within the liver disease group, cirrhosis dominated the diagnostic landscape, accounting for 45.9 percent of cases, making advanced scarring of the liver the single most common underlying hepatic disorder among the affected patients.

The laboratory data revealed a striking biochemical signature distinguishing the liver disease cohort. Patients with chronic liver disease showed significantly higher serum levels of aspartate aminotransferase and alanine aminotransferase, the two canonical enzymes released when hepatocytes are injured, as well as elevated bilirubin, the pigment that accumulates when the liver’s processing capacity falters. Their prothrombin times were prolonged, indicating impaired synthesis of clotting factors by a struggling liver, and their blood urea nitrogen levels were elevated, a marker that can reflect dehydration, catabolic stress, or impaired renal perfusion, all common in decompensating cirrhotic patients. These differences were statistically significant at the conventional threshold of P less than 0.05, and together they paint a picture of patients whose hepatic reserve was already compromised before the viral infection added its own burden.

Clinical presentation also diverged between the groups in ways that carry practical implications for frontline physicians. Abdominal pain and confusion were reported more frequently among patients with chronic liver disease. Both symptoms are readily explicable by hepatic pathophysiology: abdominal pain can arise from portal hypertension, ascites stretching the peritoneum, or the capsular distension of an inflamed liver, while confusion in cirrhotic patients frequently signals hepatic encephalopathy, the neuropsychiatric syndrome caused when the failing liver fails to clear ammonia and other neurotoxic metabolites from the circulation. The overlap between encephalopathy and the confusion of severe COVID-19 hypoxia presents a genuine diagnostic challenge, and the study’s finding underscores that clinicians evaluating a confused COVID-19 patient with known liver disease must consider both mechanisms simultaneously.

The central result of the study concerns survival. After accounting for the comparison design, the researchers found that chronic liver disease was associated with higher odds of in-hospital mortality compared with the selected non-CLD comparison group. In other words, even against counterparts who were similar in age and free of other recorded chronic conditions, patients whose livers were chronically diseased died in the hospital at a meaningfully higher rate. This aligns with the mechanistic expectations that motivated the study in the first place. Patients with chronic liver disease are considered particularly vulnerable to COVID-19 because of immune dysregulation, chronic inflammation, and impaired metabolic function, a triad that leaves them less equipped to mount an effective antiviral response and more prone to the runaway inflammatory cascades that characterize severe disease.

The mechanistic plausibility of this vulnerability rests on well-characterized biology. The angiotensin-converting enzyme 2 receptor, which SARS-CoV-2 uses to enter cells, is expressed on cholangiocytes, the epithelial cells lining the bile ducts, providing a potential route for direct viral injury to the biliary tree and, indirectly, to hepatocytes. Beyond direct infection, the systemic inflammation of severe COVID-19, driven by elevated interleukin-6 and C-reactive protein, can precipitate decompensation in a cirrhotic liver that was already operating near its functional ceiling. The coagulopathy of COVID-19, marked by prolonged prothrombin times and elevated D-dimers in the sickest patients, compounds the baseline coagulation abnormalities of advanced liver disease, creating a convergent prothrombotic and prohemorrhagic hazard that neither condition alone would produce to the same degree.

Not every measured outcome differed between the groups, and the negative findings are themselves informative. The duration of hospitalization was statistically indistinguishable between patients with and without chronic liver disease, with a P value of 0.972, suggesting that among those who survived, the liver disease did not prolong the hospital stay in this cohort. The study also evaluated intensive care unit admission as an outcome, alongside demographic characteristics, clinical manifestations, laboratory parameters, and treatment outcomes, providing a broad clinical picture of how the two cohorts fared across the arc of their admissions. Analyses were performed using SPSS version 26, the standard statistical package for medical cohort studies of this scale.

The authors are careful to flag the boundaries of what their data can support. Because subgroup analyses according to cirrhosis status were not performed, no conclusions can be drawn from this cohort regarding the specific association between cirrhosis itself and clinical outcomes, even though cirrhosis was the most common underlying disorder among the liver disease patients. This is a meaningful limitation, since cirrhosis represents the extreme end of the chronic liver disease spectrum, and its specific contribution to COVID-19 mortality has been debated in the international literature. The single-center design at one hospital in Babol, and the modest sample size of 37 exposed patients, further counsel caution in generalizing the effect estimates to other populations and health care settings.

Nevertheless, the study’s practical message for clinicians is clear and actionable. A hospitalized COVID-19 patient with chronic liver disease should be recognized from the outset as belonging to a higher-risk category, warranting closer laboratory surveillance of transaminases, bilirubin, and coagulation parameters, a lower threshold for investigating altered mental status as possible encephalopathy, and heightened vigilance for the decompensation events, such as variceal bleeding, infection, and renal failure, that convert chronic hepatic disease into acute organ failure. The research was approved by the Ethics Committee of Babol University of Medical Sciences under code IR.MUBABOL.REC.1402.155, received no external funding, and was published open access on 6 October 2026, with the authors declaring no competing interests. As the pandemic’s legacy continues to be mapped across vulnerable populations, studies of this kind sharpen the clinical stratification tools that determine which patients need the most aggressive monitoring when SARS-CoV-2 arrives on the ward.

Subject of Research: The association between chronic liver disease and clinical outcomes, including in-hospital mortality, in patients hospitalized with COVID-19.

Article Title: Association of chronic liver disease with clinical outcomes and in-hospital mortality among hospitalized patients with COVID-19: a retrospective cohort study from Northern Iran

Article References: Zabihi, R., Abedi, S. H., Shirafkan, H., Dehpanah, A. A., Raei, A., Zebardast, A., & Yahyapour, Y. (2026). Association of chronic liver disease with clinical outcomes and in-hospital mortality among hospitalized patients with COVID-19: a retrospective cohort study from Northern Iran. Gut Pathogens. https://doi.org/10.1186/s13099-026-00888-4

Image Credits: AI Generated

DOI: 10.1186/s13099-026-00888-4

Keywords: COVID-19, chronic liver disease, cirrhosis, SARS-CoV-2, in-hospital mortality, clinical outcomes, retrospective cohort study, liver enzymes, hepatic encephalopathy, Iran, Gut Pathogens, coagulopathy

The research, led by Huimin Liu, Yan Zhu, Wenting Chen, Shilian Li and colleagues working across the Third Affiliated Hospital of Chongqing Medical University, Southwest Hospital of the Army Medical University and the Chongqing Key Laboratory for Research of Viral Infectious Diseases, took advantage of a clinically diverse patient cohort in a region where hepatitis B virus infection remains a dominant cause of liver disease. In total, 80 patients with chronic liver disease were prospectively recruited: 53 with hepatitis B virus infection, 7 with alcohol-associated liver disease, 6 with drug-induced liver injury, and 14 with liver disease arising from other or unknown causes. Forty demographically matched healthy individuals served as controls, giving the team a reference baseline against which disease-associated changes could be measured.

What distinguishes this investigation from many prior microbiome surveys is its dual-omics design combined with sampling at two sites along the intestinal tract. Fecal samples were collected from all enrolled participants and subjected to metagenomic sequencing, a technique that reads the collective genetic material of the gut microbial community and allows researchers to identify not only which microbes are present but also which functional genes and metabolic pathways they encode. In parallel, the team performed non-targeted metabolomic profiling on the same fecal specimens, capturing the small-molecule chemical landscape produced by the joint activity of microbes and host metabolism. Crucially, in a 25-patient subset, the investigators also obtained small intestinal mucosal biopsies, which were likewise sequenced metagenomically, offering a rare glimpse of the microbial ecology of the upper intestine, the segment of the gut most directly connected to the liver through the portal circulation.

This anatomical dimension matters because of the gut-liver axis, the bidirectional communication system linking the intestine and the liver. Nutrients, microbial products and bacterial metabolites absorbed from the intestine travel directly to the liver through the portal vein, and the liver in turn shapes the intestinal environment through bile acid secretion and immune factors. When the liver is chronically injured, bile acid metabolism and gut motility are often disrupted, which can promote bacterial overgrowth in the small intestine and increase the translocation of microbial products into the portal circulation, fueling inflammation and further liver damage. By sampling both feces and small intestinal mucosa, the study was able to map microbial features at multiple points along this axis rather than relying solely on stool as a proxy.

The exploratory analyses suggested that the different etiologies of chronic liver disease are associated with potentially distinct microbiome and metabolome profiles. The alcohol-associated liver disease group stood out in particular, showing differences in microbial composition and in predicted functional pathways compared with the other groups. This observation is biologically plausible: alcohol and its metabolites directly alter the intestinal environment, disrupt tight junctions between epithelial cells, and select for microbial communities capable of metabolizing ethanol and producing endotoxins. However, the authors are careful to emphasize that the alcohol-associated group comprised only seven patients, and the findings for this subgroup should therefore be interpreted cautiously until they are confirmed in larger cohorts.

On the metabolic side, the non-targeted metabolomic analysis identified etiology-associated metabolic features that separated the disease groups within this cohort. Several metabolite panels showed preliminary discriminatory potential, meaning that combinations of small molecules in fecal samples could, in principle, help distinguish patients with different underlying causes of liver disease. Such metabolic signatures are attractive candidates for non-invasive biomarkers because they can be measured in stool or blood without the need for liver biopsy, which remains the invasive gold standard for assessing liver pathology. The researchers also note that trimethylamine N-oxide, a gut microbe-derived metabolite previously implicated in cardiovascular and metabolic disease, belongs to the class of microbial metabolites of interest in liver disease research, illustrating the clinical relevance of this chemical dimension of the gut-liver axis.

Perhaps the most technically ambitious component of the study was the integrated mapping of microbiome and metabolome data. By correlating specific microbial taxa with specific metabolic pathways, the team uncovered associations pointing toward host-microbe interactions along the gut-liver axis. This kind of integration is essential because microbial composition alone does not reveal function: two communities may contain different species yet perform overlapping metabolic roles, or the same species may behave differently depending on its genomic repertoire and environmental context. Linking who is present with what they are doing chemically brings the field closer to understanding mechanisms rather than merely cataloging correlations, and it generates concrete hypotheses about how microbial products might contribute to liver injury or, conversely, how liver dysfunction reshapes the microbial ecosystem.

The authors are explicit about the limitations of their work, and this transparency is an important part of the study’s scientific value. The cohort, while diverse, was modest in size and unbalanced across etiologies, with hepatitis B virus infection dominating the enrollment and the alcohol-associated, drug-induced and other-cause groups represented by only a handful of patients each. As an exploratory study, it identifies candidate microbial and metabolic features rather than definitive biomarkers, and all associations require validation in larger, well-balanced and independent cohorts before any clinical application can be contemplated. The study was conducted in accordance with the Declaration of Helsinki, with ethical approval from the Ethics Committee of the Army Medical University and informed consent from all participants, and the authors declare no competing interests. The work was supported by the National Key Research and Development Program of China and the Chongqing Medical Scientific Research Project.

Even with these caveats, the study arrives at a moment of growing enthusiasm for microbiome-based approaches in hepatology. Researchers worldwide are investigating whether fecal microbial signatures can predict disease progression, whether microbial metabolites mediate complications such as hepatic encephalopathy, and whether interventions ranging from diet and probiotics to fecal microbiota transplantation can modify the course of liver disease. Multi-omics studies of this kind supply the reference maps on which such efforts depend. By simultaneously profiling bacteria, their genes, their chemical products and the upper intestinal mucosa, the Chinese team has generated a rich dataset that other investigators can interrogate, replicate and extend.

The next steps are clear. Larger cohorts with balanced representation of viral, alcoholic, drug-induced and metabolic liver disease will be needed to confirm which microbial taxa and metabolites truly distinguish each etiology, and longitudinal designs will be required to determine whether these signatures precede disease progression or merely accompany it. If validated, etiology-specific microbiome and metabolome panels could eventually complement existing clinical tests, helping physicians identify the cause of liver injury more rapidly, stratify patients for targeted therapies, and monitor responses to treatment through simple, non-invasive sampling. For now, this study stands as a carefully executed exploratory milestone, demonstrating that the chemical and biological conversation between gut and liver carries etiology-specific information that modern sequencing and metabolomic technologies are finally able to read.

Subject of Research: Gut microbiome and metabolome profiles across diverse etiologies of chronic liver disease

Article Title: Gut microbiome and metabolome profiles in diverse etiologies of chronic liver disease

Article References: Liu, H., Zhu, Y., Chen, W., Li, S., Ma, X., Chen, F., Zhao, S., Wu, Y., Zheng, S., Ran, L., Deng, G., Zeng, B., Mao, Q., & Zhang, X. (2026). Gut microbiome and metabolome profiles in diverse etiologies of chronic liver disease. Gut Pathogens. https://doi.org/10.1186/s13099-026-00877-7

Image Credits: AI Generated

DOI: 10.1186/s13099-026-00877-7

Keywords: chronic liver disease, gut microbiome, metabolome, metagenomics, gut-liver axis, hepatitis B virus, alcohol-associated liver disease, drug-induced liver injury, metabolomics, biomarkers, small intestine, multi-omics